Y-MABS THERAPEUTICS,INC. (NASDAQ: YMAB) Files An 8-K Other Events

Y-MABS THERAPEUTICS,INC. (NASDAQ: YMAB) Files An 8-K Other Events
Item 8.01

Story continues below

On December10, 2018, Y-mAbs Therapeutics,Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has cleared the Investigational New Drug (“IND”) application for a humanized bispecific GD2 antibody. It is anticipated that a Phase 1/2 clinical trial will soon be initiated to begin screening patients with relapsed/refractory neuroblastoma, high grade osteosarcoma and other GD2(+) solid tumors, where patients have relapsed or refractory disease that is resistant to standard therapy. A copy of the press release is attached hereto as Exhibit99.1.

The information furnished to Item 8.01 on this Form8-K, including Exhibit99.1 attached hereto, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01. Financial Statements and Exhibits.

(d)Exhibits


Y-mAbs Therapeutics, Inc. Exhibit
EX-99.1 2 a18-41361_1ex99d1.htm EX-99.1 Exhibit 99.1       Y-mAbs Therapeutics Announces FDA Clearance of IND for its Bispecific GD2 Antibody   New York,…
To view the full exhibit click here

An ad to help with our costs